Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine

Journal of Zhejiang University: Science B

Volumn 14, Issue 8, 2013, Pages 696-704

  Shi, Ya Fei ^a,b   Chi, Ju Fang ^a   Tang, Wei Liang ^a   Xu, Fu Kang ^a   Liu, Long Bin ^a   Ji, Zheng ^a   Lv, Hai Tao ^a   Guo, Hang Yuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Homocysteine; Matrix metalloproteinase 2 (MMP 2); Migration; Rosuvastatin; Vascular smooth muscle cells (VSMCs)

Indexed keywords

GELATIN; GELATINASE A; HOMOCYSTEINE; ROSUVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WISTAR RAT; ZYMOGRAPHY;

EID: 84881431120     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.BQICC703     Document Type: Article

References (25)

1. Arnaboldi, L., Guzzetta, M., Pazzucconi, F., Radaelli, G., Paoletti, R., Sirtori, C.R., Corsini, A., 2007. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol. Res., 56(6):503-508. [doi:10.1016/j.phrs.2007.09. 012]
2. Bescond, A., Augier, T., Chareyre, C., Garçon, D., Hornebeck, W., Charpiot, P., 1999. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem. Biophys. Res. Commun., 263(2):498-503. [doi:10.1006/bbrc.1999.1391]
3. Busti, C., Falcinelli, E., Momi, S., Gresele, P., 2010. Matrix metalloproteinases and peripheral arterial disease. Intern. Emerg. Med., 5(1):13-25. [doi:10.1007/s11739-009-0283-y]
4. Castro, R., Rivera, I., Blom, H.J., Jakobs, C., Tavares, de Almeida, I., 2006. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J. Inherit. Metab. Dis., 29(1):3-20. [doi:10.1007/s10545-006-0106-5]
5. Cheng-Lai, A., 2003. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis., 5(1):72-78. [doi:10.1097/01.HDX.0000050417.89309.F8]
6. Guo, H., Lee, J.D., Ueda, T., Shan, J., Wang, J., 2003. Plasma homocysteine levels in patients with early coronary artery stenosis and high risk factors. Jpn. Heart J., 44(6): 865-871. [doi:10.1536/jhj.44.865]
7. Guo, H., Lee, J.D., Uzui, H., Yue, H., Wang, P., Toyoda, K., Geshi, T., Ueda, T., 2007. Effects of heparin on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells. Can. J. Cardiol., 23(4):275-280. [doi:10.1016/S0828-282X(07)70754-7]
8. Guo, H., Liu, L., Shi, Y., Sun, A., Xu, F., Chi, J., Huang, D., 2010. Chinese yellow wine and red wine inhibit matrix metalloproteinase-2 and improve atherosclerotic plaque in LDL receptor knockout mice. Cardiovasc. Ther., 28(3): 161-168. [doi:10.1111/j.1755-5922.2009.00132.x]
9. Hagar, H.H., 2002. Folic acid and vitamin B12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol. Res., 46(3):213-219. [doi:10.1016/S1043-6618(02)00095-6]
10. Holven, K.B., Aukrust, P., Holm, T., Ose, L., Nenseter, M.S., 2002. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler. Thromb. Vasc. Biol., 22(4):699-703. [doi:10.1161/01.ATV.0000013288.35930.90]
11. Kuzuya, M., Kanda, S., Sasaki, T., Tamaya-Mori, N., Cheng, X.W., Itoh, T., Itohara, S., Iguchi, A., 2003. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation, 108(11):1375-1381. [doi:10.1161/01.CIR.00000 86463.15540.3C]
12. Li, D., Chen, H., Romeo, F., Sawamura, T., Saldeen, T., Mehta, J.L., 2002. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J. Pharmacol. Exp. Ther., 302(2):601-605. [doi:10.1124/jpet.102.034959]
13. Libby, P., Okamoto, Y., Rocha, V.Z., Folco, E., 2010. Inflammation in atherosclerosis: transition from theory to practice. Circ. J., 74(2):213-220. [doi:10.1253/circj.CJ-09-0706]
14. Löffek, S., Schilling, O., Franzke, C.W., 2011. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance. Eur. Respir. J., 38(1):191-208. [doi:10.1183/09031936.00 146510]
15. Luan, Z., Chase, A.J., Newby, A.C., 2003. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol., 23(5):769-775. [doi:10.1161/01.ATV.0000068646.76823.AE]
16. Moshal, K.S., Sen, U., Tyagi, N., Henderson, B., Steed, M., Ovechkin, A.V., Tyagi, S.C., 2006. Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am. J. Physiol. Cell Physiol., 290(3):C883-C891. [doi:10.1152/ajpcell. 00359.2005]
17. Newby, A.C., 2005. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev., 85(1):1-31. [doi:10.1152/physrev.00048.2003]
18. Puccetti, L., Acampa, M., Auteri, A., 2007. Pharmacogenetics of statins therapy. Recent Pat. Cardiovasc. Drug Discov., 2(3):228-236. [doi:10.2174/157489007782418982]
19. Raffetto, J.D., Khalil, R.A., 2008. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol., 75(2):346-359. [doi:10.1016/j.bcp.2007.07.004]
20. Steed, M.M., Tyagi, S.C., 2011. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid. Redox Signal., 15(7):1927-1943. [doi:10.1089/ars.2010.3721]
21. Uzui, H., Lee, J.D., Shimizu, H., Tsutani, H., Ueda, T., 2000. The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis, 149(1):51-59. [doi:10.1016/S0021-9150(99)00295-6]
22. Verreth, W., de Keyzer, D., Davey, P.C., Geeraert, B., Mertens, A., Herregods, M.C., Smith, G., Desjardins, F., Balligand, J.L., Holvoet, P., 2007. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br. J. Pharmacol., 151(3):347-355. [doi:10.1038/sj.bjp. 0707231]
23. Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., Payne, N., 2007. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess, 11(14):1-160, iii-iv.
24. Weber, C., Noels, H., 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med., 17(11): 1410-1422. [doi:10.1038/nm.2538]
25. Zhou, J., Austin, R.C., 2009. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors, 35(2):120-129. [doi:10.1002/biof.17]